US EditionPublished • loading... • Updated
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
The biotech company plans to fund research, clinical development and manufacturing costs with net proceeds from the share sale.
- On Tuesday, San Francisco-based Nektar Therapeutics announced the pricing of an upsized underwritten public offering of approximately $325 million in common stock.
- Proceeds from the offering are intended for general corporate purposes, including research and development and manufacturing costs to support advancement of Nektar's drug candidates, particularly REZPEG.
- Jefferies, Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering, which is expected to close on Thursday, April 23, 2026, subject to customary conditions.
- A final prospectus supplement describing the offering terms will be filed with the SEC, pursuant to a shelf registration statement filed on November 12, 2025.
- Nektar is currently evaluating REZPEG in Phase 2b clinical trials for atopic dermatitis and alopecia areata, with Phase 3 trials planned, while the pipeline includes bispecific programs NKTR-0165 and NKTR-0166.
Insights by Ground AI
21 Articles
21 Articles
Montana Standard+17 Reposted by 17 other sources
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million…
Coverage Details
Total News Sources21
Leaning Left0Leaning Right0Center11Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
